Lévi, Francis
,
Karaboué, Abdoulaye
Saffroy, Raphaël
Desterke, Christophe
Boige, Valerie
Smith, Denis
Hebbar, Mohamed
Innominato, Pasquale
Taieb, Julien
Carvalho, Carlos
Guimbaud, Rosine
Focan, Christian
Bouchahda, Mohamed
Adam, René
Ducreux, Michel
Milano, Gérard
Lemoine, Antoinette
Article History
Received: 15 May 2017
Revised: 18 July 2017
Accepted: 24 July 2017
First Online: 17 August 2017
Competing interests
: VB has consulted or advised for Merck Serono, Amgen, Sanofi-Aventis, Bayer and Prestizia; has received honoraria from Amgen, Merck Serono, Bayer, Roche, Novartis and Daiichi Sankyo; has received travel grants from Amgen, Merck Serono, Sanofi and Bayer; has received research funding from Merck Serono. JT has received honoraria from Merck, Amgen, Roche, Celgene, Sanofi, Lilly, Baxalta and Sirtex. RG has received travel grants Roche, Novartis, Ipsen, Sanofi and Lilly. RA has consulted or advised for Merck and Amgen; has received honoraria from Amgen, Merck, Sanofi and Astellas; and has received travel grants from Amgen, Merck, Sanofi and Astellas. MD has consulted or advised for Roche, Merck Serono, Amgen, Bohringer, Servier and Celgene; has received honoraria from Merck Serono, Roche, Amgen, Novartis, Lilly, Bayer, Ipsen, Servier and Celgene; has received travel grants from Roche, Merck Serono, Ipsen, Bayer and Celgene; and has received research funding from Merck Serono, Pfizer and Roche. His wife is Head of Business Unit Oncology of Sandoz. GM has consulted or advised for Merck, Pierre Fabre and Onxeo; has received honoraria from Merck, Roche, BMS, Novartis, Amgen and Pierre Fabre. The remaining authors declare no conflict of interest.